ClinicalTrials.gg
Sign In
CompletedNCT07891975Updated Oct 23, 2026

Modulatory Effects of Resveratrol Supplement Along With and Without Low Glycemic Index Diet Among Obese Patients With Diabetic Nephropathy

An interventional study of T0 starch capsule and T1 resveratrol capsule in Liver Biomarkers, Glucose and Lipid Profiles, sponsored by University of Lahore. Completed at 1 site in Pakistan. Open to participants aged 40 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by University of Lahore · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jun 2025, registered Jun 2026).
Updated Oct 23, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
All
01

Study summary

This 12-week randomized controlled trial evaluated the effects of resveratrol supplementation with and without a low glycemic index (LGI) diet in obese patients with diabetic nephropathy. Resveratrol, particularly at the higher dose combined with an LGI diet, significantly improved anthropometric, hepatic, renal, and biochemical parameters, including BMI, liver enzymes, BUN, UPCR, serum uric acid, phosphorus, and albumin levels. These findings suggest that resveratrol may serve as an effective nutraceutical adjunct to dietary modification for improving renal and metabolic health in diabetic nephropathy patients.

Read the detailed description

This randomized controlled trial investigated the modulatory effects of resveratrol supplementation, with and without a low glycemic index (LGI) diet, among 102 obese patients with diabetic nephropathy over a 12-week intervention period. Participants were randomly allocated into three groups, including a placebo group and two treatment groups receiving different doses of resveratrol. Clinical, anthropometric, and biochemical parameters were assessed at baseline and after the intervention to determine the efficacy of the treatments.

02

Conditions studied

  • Liver Biomarkers
  • Glucose
  • Lipid Profiles

Keywords

  • diabetic nephropathy
  • obesity
  • diabetes mellitus
  • renal diseases
03

In context

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 107 are open to participants now.

This study's enrollment of 102 is above the median of 80 across 385 interventional studies indexed under Diabetic Nephropathies.

Browse Diabetic Nephropathies studies →

Lead sponsor

University of Lahore is the lead sponsor of 230 studies on the registry; 41 are open to participants now.

Browse University of Lahore studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:• Adults aged (40-60) years

  • Obese individuals - BMI ≥ 30.0 kg/m²
  • Individuals with Fasting Plasma Glucose (FPG) ≤130 mg/dL
  • Individuals with HbA1c ≤ 8% (≤64 mmol/mol).
  • Urine albumin-creatinine ratio (UACR) ≥30 mg/g
  • Serum creatinine ≤2 mg/dL.
  • Blood urea nitrogen (BUN) ≤ 20 mg/dL
  • Estimated GFR (eGFR) ≥ 60 ml/min
  • Inflammatory and stress biomarkers through TNF-α > 8.1 pg/mL and C-Reactive Protein (CRP) > 3 mg/L.
  • Liver function test markers, ALT > 56 U/L, AST > 40 U/L, ALP > 147 U/L.
  • Lipid profile levels, TC ≥ 200 mg/dL, TG ≥ 150 mg/dL, LDL ≥ 100 mg/dL, HDL ≤ 40 mg/dL.

Exclusion Criteria:• Pregnancy or lactation.

  • Allergic to resveratrol.
  • Liver failure (acute or chronic).
  • Uncontrolled hypertension (BP ≥140/90 mmHg).
  • Congestive heart failure.
  • History of malignancy.
  • Bilateral renal artery stenosis.
  • Any systemic disease other than diabetes.
  • Active infection or rheumatological disorder.
  • Use of warfarin or other anticoagulants.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
102 participants (actual)

Study arms

  • Placebo comparator
    PLACEBO T0

    1 starch capsule of 300 mg along with their regular diet

    Dietary Supplement: T0 starch capsule

  • Experimental
    1 resveratrol capsule of 300 mg per day T1

    1 resveratrol capsule of 300 mg per day along with a low glycemic index diet, once a day

    Dietary Supplement: T1 resveratrol capsule

  • Experimental
    1 resveratrol capsules of 300 mg per day along with a low glycemic index diet, TWICE A DAY T2

    1 resveratrol capsules of 300 mg per day along with a low glycemic index diet, TWICE A DAY

    Dietary Supplement: T2 300 mg per day along with a low glycemic index diet, TWICE A DAY

Interventions

  • Dietary supplementT0 starch capsule

    1 starch capsule of 300 mg along with their regular diet

  • Dietary supplementT1 resveratrol capsule

    1 resveratrol capsule of 300 mg per day along with a low glycemic index diet, ONCE A DAY

  • Dietary supplementT2 300 mg per day along with a low glycemic index diet, TWICE A DAY

    1 resveratrol capsule of 300 mg per day along with a low glycemic index diet, TWICE A DAY

06

What researchers measure

Primary outcomes

  1. LIVER ENZYMES

    liver enzymes were assessed (AST, ALT, ALP)

    Time frame: 12 WEEKS

  2. LIPID PROFILE (TC,TG,LDL, HDL)

    lipid profile assessed

    Time frame: 12 week

  3. GLUCOSE (Fasting glucose)

    fasting glucose assessed

    Time frame: 12 weeks

  4. weight (kg)

    weight

    Time frame: 12 weeks

Secondary outcomes

  1. INFLAMAMATION

    inflammation was assessed through CRP

    Time frame: 12 WEEKS

07

Study locations

1 site
  • Sana Noreen
    Lahore, Punjab Province 54000, Pakistan
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Aug 2025, 2 months.

Of 50 non-industry interventional studies with no phase under Diabetic Nephropathies, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 2 months is below that.

Counting every sponsor, half of 53 studies reached it within 23 months; a quarter within 10 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2026
First posted
Oct 23, 2026
StartActual
Jun 2, 2025
Primary completionActual
Aug 10, 2025
CompletionActual
Sep 7, 2025
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07891975
Lead sponsor
University of Lahore
Responsible party
Sponsor
First posted
Oct 23, 2026
Start date
Jun 2, 2025
Primary completion
Aug 10, 2025
Completion
Sep 7, 2025
Last update
Oct 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Diabetic Nephropathies →

Other studies from this sponsor

University of Lahore →

Start the discussion